Efficacy and Safety of Sodium Oxybate in Isolated Focal Laryngeal Dystonia: A Phase <scp>IIb</scp> Double‐Blind Placebo‐Controlled Cross‐Over Randomized Clinical Trial
Sodium oxybate showed clinically meaningful improvement of symptoms in EtOH+ LD patients, with acceptable tolerability. Sodium oxybate offers the first pathophysiologically relevant oral treatment for laryngeal dystonia. ANN NEUROL 2025;97:329-343.
Authors
- Kristina Simonyan (ORCID: https://orcid.org/0000-0001-7444-0437)
- Azadeh Hamzehei Sichani (ORCID: https://orcid.org/0000-0001-7253-3277)
- Nutan Sharma (ORCID: https://orcid.org/0000-0002-4445-7374)
- Anna F. Rumbach (ORCID: https://orcid.org/0000-0002-6542-4942)
- Lena C. O’Flynn (ORCID: https://orcid.org/0000-0001-6368-0793)
- Alexis Worthley
- Steven J. Frucht (ORCID: https://orcid.org/0000-0002-4653-0491)
- Phillip C. Song (ORCID: https://orcid.org/0000-0003-0206-5441)
Institutions
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- The University of Queensland (AU)
- Speech Pathology Australia (AU)
- NYU Langone Health (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Annals of Neurology
- Published
- 2024-11-20
- DOI
- https://doi.org/10.1002/ana.27121
- Citations
- 10
- Primary Topic
- Botulinum Toxin and Related Neurological Disorders
- Type
- article
- Field-Weighted Citation Impact
- 3.69
Funders
- Jazz Pharmaceuticals
- National Institutes of Health
- National Institute on Deafness and Other Communication Disorders